Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) is a pioneering synthetic biotechnology company that leverages its Lab-to-Market™ technology platform to facilitate the world's shift towards sustainable consumption. Founded with the vision of transforming the Clean Health & Beauty and Flavors & Fragrances markets, Amyris specializes in converting plant sugars into essential hydrocarbon molecules, specialty ingredients, and consumer products using innovative bioscience solutions. The company's proprietary technology platform utilizes advanced machine learning, robotics, and artificial intelligence to bring new innovations to market at commercial scale, resulting in products incorporated into over 20,000 items from leading global brands, impacting more than 300 million consumers.
Recently, Amyris has undergone significant changes to optimize its operations and financial health. In June 2023, the company announced the resignation of its President & CEO, John Melo, with Han Kieftenbeld stepping in as Interim CEO while continuing his role as CFO. This leadership change aligns with Amyris' broader strategy to streamline its business and achieve cost reduction targets, including a global reduction in force and collaboration with PricewaterhouseCoopers (PwC) to implement 'Fit-to-Win' cost actions estimated at $250 million.
Further advancing its strategic transformation, Amyris commenced voluntary Chapter 11 proceedings in August 2023 to restructure its operations and financial framework. This restructuring aims to enhance the company's cost structure, capital position, and liquidity, allowing it to refocus on its core competencies in research and development, commercialization, and the application of sustainable ingredients through biofermentation. As part of this effort, Amyris plans to exit from its consumer brands, marketing them for sale while continuing to operate them through retail and e-commerce platforms during the transition.
Amyris has secured $190 million in debtor-in-possession financing from Foris Ventures to support its daily operations and meet its commitments to employees, customers, and partners throughout the restructuring process. The company is committed to maintaining its innovative edge and remains dedicated to introducing sustainable, effective, and accessible products to market, ensuring a path toward profitable growth and sustained cash generation.
More information about Amyris and its ongoing projects and initiatives can be found on their official website, www.amyris.com.
Amyris, Inc. (Nasdaq: AMRS) announced that its Pipette clean baby care brand will expand to over 600 Target stores across North America starting in March 2021. Since its 2019 launch, Pipette has seen significant growth, particularly among Millennial parents, with year-to-date retail sales trending over 8 times higher than the same period in 2020. Pipette products are known for being 100% nontoxic and EWG verified. This retail expansion builds on existing e-commerce momentum and solidifies Pipette's position in the sustainable personal care market.
Amyris announced promising preliminary data on its RNA COVID-19 vaccine platform, developed in collaboration with IDRI. This technology shows significant antibody production against the COVID-19 spike protein and is set to enter phase 1 clinical trials. The platform could address manufacturing and distribution challenges, including storage at refrigerator and room temperatures, improving accessibility in low-resource areas. Amyris is pursuing U.S. government funding to scale production and enhance its sustainable ingredient offerings.
Amyris, Inc. (Nasdaq: AMRS) will report its fourth quarter and full year 2020 financial results on March 2, 2021, before market opening. The release will be followed by a conference call at 6:00 am PT. CEO John Melo, CFO Han Kieftenbeld, and COO Eduardo Alvarez will discuss the financial results and business updates. Amyris focuses on sustainable ingredients for Clean Health and Beauty markets and owns three consumer brands: Biossance, Pipette, and Purecane. More information can be found on their website.
Amyris, Inc. (Nasdaq: AMRS) successfully conducted its second webinar in the virtual investor mini-series themed "Delivering on the Promise of Synthetic Biology" on February 9, 2021. The event attracted over 600 attendees, featuring insights from key executives including CEO John Melo and CFO Han Kieftenbeld. Highlights included updates on strategic transactions, the beauty market, and planned product launches in 2021, with a focus on expansion in China. A replay of the webinar is available on Amyris's investor relations website.
Amyris, a leader in synthetic biotechnology, announced its second webinar in the virtual investor mini-series titled "Delivering on the Promise of Synthetic Biology". Scheduled for February 9, 2021, at 1:00 PM ET, this session focuses on The Science Delivering Clean and Sustainable Consumer Products, featuring a business update and Q&A. This format allows for targeted engagement on specific investor topics, with a third session following later in Q2 2021. The live event can be accessed via Amyris's investor relations site.
Amyris, Inc. (Nasdaq: AMRS) announced significant results from an early clinical study of its clean topical acne formulation made from fermentation-based ingredients. Conducted by Princeton Consumer Research, the study showed Amyris's formulation performed better than 10 standard acne treatments in terms of efficacy and speed of acne reduction. The global acne treatment market is valued at $11 billion, with increasing demand due to conditions like 'maskne'. Amyris aims to finalize this formulation for consumer launch, potentially positioning itself as a leader in the clean beauty market.
Amyris, Inc. (Nasdaq: AMRS) announced on January 22, 2021, the launch of its Terasana brand, which will offer clean beauty products made from sustainably sourced natural cannabinoids. This move expands Amyris's clean beauty portfolio beyond existing brands like Biossance and Pipette. The company leverages its proprietary Lab-to-Market synthetic biology platform to create effective skincare solutions using CBG (cannabigerol) derived from sugarcane. Early clinical results indicate that these CBG formulations outperform standard CBD products for various skin conditions, positioning Amyris favorably in the cannabinoid market.
Amyris, Inc. (Nasdaq: AMRS) has been recognized as one of the top global organizations for social and environmental impact, ranked #23 out of 150 by Real Leaders in their 2021 Impact Awards. This achievement is attributed to Amyris's rapid revenue growth, which doubled from 2017 to 2019, showcasing its potential in sustainable products. The company is expanding its consumer brands, including new haircare offerings and entering the Greater China market. The awards ceremony will take place on January 27, 2021.
Amyris, Inc. (Nasdaq: AMRS) announced a new partnership with Jonathan Van Ness to launch a clean haircare brand, aiming to revolutionize the industry with sustainable, effective products. Expected to launch in summer 2021, the brand will utilize Amyris's proprietary hemi-squalane ingredient for enhanced hair health across all textures. This move expands Amyris's footprint in the clean beauty market, which represents a significant segment of the $300 billion beauty industry, furthering its commitment to inclusivity and environmentally friendly products.
Amyris, Inc. (Nasdaq: AMRS) announced its entry into the Greater China market with its Biossance Clean Beauty brand, partnering with SuperOrdinary Group. This collaboration positions Biossance within one of the fastest-growing beauty markets where consumers prioritize sustainable products. The partnership aims to leverage SuperOrdinary's expertise in establishing leading brands in China. Amyris expects significant growth, citing strong fourth-quarter sales and aiming for sales revenue equivalent to all of 2019. This strategic move aligns with the increasing demand for clean beauty products in China.
FAQ
What does Amyris, Inc. specialize in?
What is the Lab-to-Market™ technology platform?
Who is the current CEO of Amyris?
What recent strategic changes has Amyris implemented?
How is Amyris supporting its operations during the restructuring?
What is Amyris' 'Fit-to-Win' initiative?
Will Amyris continue to operate its consumer brands?
What is the impact of Amyris' products on the market?
How can stakeholders get more information about Amyris' restructuring?
Where can I find more information about Amyris?
